No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TMDX TransMedics
- 136.140
- +3.700+2.79%
Close May 15 16:00 ET
- 135.000
- -1.140-0.84%
Post 16:16 ET
4.48BMarket Cap-400411P/E (TTM)
137.590High133.039Low706.62KVolume134.660Open132.440Pre Close95.85MTurnover2.22%Turnover RatioLossP/E (Static)32.94MShares137.59052wk High28.12P/B4.34BFloat Cap36.42052wk Low--Dividend TTM31.89MShs Float137.590Historical High--Div YieldTTM3.44%Amplitude10.000Historical Low135.650Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) Is a Great Choice
(SEC Amendment) TransMedics(TMDX.US) Officer Sells US$6.87 Million in Common Stock
$TransMedics(TMDX.US)$ Officer Khayal Tamer I sold 63,260 shares of common stock on May 1, 2024 at an average price of $108.54 for a total value of $6.87 million.Source: Announcement What is statement
TransMedics(TMDX.US) Director Sells US$324.55K in Common Stock
$TransMedics(TMDX.US)$ Director Weill David sold 2,500 shares of common stock on May 10, 2024 at an average price of $129.82 for a total value of $324.55K.Source: Announcement What is statement of cha
Form 144 | TransMedics(TMDX.US) Director Proposes to Sell 326.75K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $TransMedics(TMDX.US)$ Director Weill David intends to sell 2,500 shares of its common stock on May 10, with a total market value of approximately $326.75K. Source:
Insiders At TransMedics Group Sold US$3.7m In Stock, Alluding To Potential Weakness
In the last year, many TransMedics Group, Inc. (NASDAQ:TMDX) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it
Insider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX)
Comments
TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
1
$Advanced Micro Devices(AMD.US$ was obvious to buy at $100 and many waited
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
9
3
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Insider selling over the past year, particularly in recent months, may indicate insiders believe shares are overpriced. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership shows alignment with shareholders, but past sales warrant caution.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg